In-person versus virtual administration of the American College of Rheumatology gold standard cognitive battery in systemic lupus erythematosus : Are they interchangeable?
OBJECTIVE: During the COVID-19 pandemic, many research studies were adapted, including our longitudinal study examining cognitive impairment (CI) in systemic lupus erythematosus (SLE). Cognitive testing was switched from in-person to virtual. This analysis aimed to determine if the administration method (in-person vs. virtual) of the ACR-neuropsychological battery (ACR-NB) affected participant cognitive performance and classification.
METHODS: Data from our multi-visit, SLE CI study included demographic, clinical, and psychiatric characteristics, and the modified ACR-NB. Three analyses were undertaken for cognitive performance: (1) all visits, (2) non-CI group visits only and (3) intra-individual comparisons. A retrospective preferences questionnaire was given to participants who completed the ACR-NB both in-person and virtually.
RESULTS: We analysed 328 SLE participants who had 801 visits (696 in-person and 105 virtual). Demographic, clinical, and psychiatric characteristics were comparable except for ethnicity, anxiety and disease-related damage. Across all three comparisons, six tests were consistently statistically significantly different. CI classification changed in 11/71 (15%) participants. 45% of participants preferred the virtual administration method and 33% preferred in-person.
CONCLUSIONS: Of the 19 tests in the ACR-NB, we identified one or more problems with eight (42%) tests when moving from in-person to virtual administration. As the use of virtual cognitive testing will likely increase, these issues need to be addressed - potentially by validating a virtual version of the ACR-NB. Until then, caution must be taken when directly comparing virtual to in-person test results. If future studies use a mixed administration approach, this should be accounted for during analysis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Lupus - 32(2023), 6 vom: 10. Mai, Seite 737-745 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Barraclough, M L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cognitive impairment |
|---|
| Anmerkungen: |
Date Completed 17.05.2023 Date Revised 19.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/09612033231168477 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355406497 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355406497 | ||
| 003 | DE-627 | ||
| 005 | 20231226064258.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/09612033231168477 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1184.xml |
| 035 | |a (DE-627)NLM355406497 | ||
| 035 | |a (NLM)37036020 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Barraclough, M L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In-person versus virtual administration of the American College of Rheumatology gold standard cognitive battery in systemic lupus erythematosus |b Are they interchangeable? |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.05.2023 | ||
| 500 | |a Date Revised 19.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a OBJECTIVE: During the COVID-19 pandemic, many research studies were adapted, including our longitudinal study examining cognitive impairment (CI) in systemic lupus erythematosus (SLE). Cognitive testing was switched from in-person to virtual. This analysis aimed to determine if the administration method (in-person vs. virtual) of the ACR-neuropsychological battery (ACR-NB) affected participant cognitive performance and classification | ||
| 520 | |a METHODS: Data from our multi-visit, SLE CI study included demographic, clinical, and psychiatric characteristics, and the modified ACR-NB. Three analyses were undertaken for cognitive performance: (1) all visits, (2) non-CI group visits only and (3) intra-individual comparisons. A retrospective preferences questionnaire was given to participants who completed the ACR-NB both in-person and virtually | ||
| 520 | |a RESULTS: We analysed 328 SLE participants who had 801 visits (696 in-person and 105 virtual). Demographic, clinical, and psychiatric characteristics were comparable except for ethnicity, anxiety and disease-related damage. Across all three comparisons, six tests were consistently statistically significantly different. CI classification changed in 11/71 (15%) participants. 45% of participants preferred the virtual administration method and 33% preferred in-person | ||
| 520 | |a CONCLUSIONS: Of the 19 tests in the ACR-NB, we identified one or more problems with eight (42%) tests when moving from in-person to virtual administration. As the use of virtual cognitive testing will likely increase, these issues need to be addressed - potentially by validating a virtual version of the ACR-NB. Until then, caution must be taken when directly comparing virtual to in-person test results. If future studies use a mixed administration approach, this should be accounted for during analysis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cognitive impairment | |
| 650 | 4 | |a neuropsychiatric lupus | |
| 650 | 4 | |a systemic lupus erythematosus | |
| 700 | 1 | |a Diaz-Martinez, J P |e verfasserin |4 aut | |
| 700 | 1 | |a Knight, A |e verfasserin |4 aut | |
| 700 | 1 | |a Bingham, K |e verfasserin |4 aut | |
| 700 | 1 | |a Su, J |e verfasserin |4 aut | |
| 700 | 1 | |a Kakvan, M |e verfasserin |4 aut | |
| 700 | 1 | |a Grajales, C Muñoz |e verfasserin |4 aut | |
| 700 | 1 | |a Tartaglia, M C |e verfasserin |4 aut | |
| 700 | 1 | |a Ruttan, L |e verfasserin |4 aut | |
| 700 | 1 | |a Wither, J |e verfasserin |4 aut | |
| 700 | 1 | |a Choi, M Y |e verfasserin |4 aut | |
| 700 | 1 | |a Bonilla, D |e verfasserin |4 aut | |
| 700 | 1 | |a Anderson, N |e verfasserin |4 aut | |
| 700 | 1 | |a Appenzeller, S |e verfasserin |4 aut | |
| 700 | 1 | |a Parker, B |e verfasserin |4 aut | |
| 700 | 1 | |a Katz, P |e verfasserin |4 aut | |
| 700 | 1 | |a Beaton, D |e verfasserin |4 aut | |
| 700 | 1 | |a Green, R |e verfasserin |4 aut | |
| 700 | 1 | |a Bruce, I N |e verfasserin |4 aut | |
| 700 | 1 | |a Touma, Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lupus |d 1991 |g 32(2023), 6 vom: 10. Mai, Seite 737-745 |w (DE-627)NLM012651214 |x 1477-0962 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2023 |g number:6 |g day:10 |g month:05 |g pages:737-745 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/09612033231168477 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2023 |e 6 |b 10 |c 05 |h 737-745 | ||